MAY 30, 2018 12:00 PM PDT

High Throughput Screening Robotics within the UK Centre for Drug Discovery

Presented at: Lab Automation 2018
Speaker
  • Director High Throughput Screening, AstraZeneca
    Biography
      Mark Wigglesworth joined AstraZeneca in Sept 2012 to lead the newly formed Global High Throughput Screening Centre. His screening experience was gained at SmithKline Beecham and GlaxoSmithKline where he worked extensively in G-Protein coupled receptor (GPCR) drug discovery initiating and leading a number of projects to deliver lead molecules to drug discovery programmes. Mark has led groups of scientists responsible for delivery of structure activity relationship data to iterative chemistry programmes as well as working within Compound Management. Mark has worked collaboratively with several academic groups and organisations such as MRC-T, has contributed to numerous publications in the field of GPCR pharmacology and Compound Management including editing a book describing the Management of Biological and Chemical Samples for Screening Applications. In his current role he leads a team of more than 20 scientists dedicated to identifying novel chemical starting points for drug discovery programmes.

    Abstract

    AstraZeneca has an ambition to create a porous organisation, seamlessly collaborating with external partners. This desire has led to the establishment of the AstraZeneca-MRC UK Centre for Lead Discovery, ultimately located in the future R&D centre in Cambridge, UK. 

    This new global screening centre encompassing AstraZeneca, Medical Research Council, Cancer Research UK and additional scientific partners has created the unique opportunity to completely re-develop our screening infrastructure and its capabilities, resulting in the concept of our next generation of HTS automation to deliver the varied capacity and assays formats across this partnership. This presentation will describe the generation, use and support for this new generation of HTS screening. 
     

    Learning Objectives: 

    1. To understand the complexity of a High Throughput Screening laboratory
    2. How collaborations can drive further success


    Show Resources
    You May Also Like
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    SEP 02, 2020 7:00 AM PDT
    C.E. CREDITS
    SEP 02, 2020 7:00 AM PDT
    DATE: September 2, 2020 TIME: 03:00pm PDT, 6:00pm EDT Spatial omics is an expanding collection of methods to examine biological molecules in their geographical context. By retaining the prec...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 12, 2020 10:00 AM PST
    NOV 12, 2020 10:00 AM PST
    Date: November 12, 2020 Time: 10:00am (PST), 1:00pm (EST) Fc receptor based affinity chromatography is a new emerging field of Fc functionality analytics. FcRn affinity columns separate anti...
    Loading Comments...
    Show Resources
    Attendees
    • See more